NeuroBo Pharmaceuticals(NRBO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update Announced Positive Top-Line Phase 1 MAD Trial Results for DA-1726 in Obesity, Demonstrating Compelling Weight Loss and Best-in-Class Potential for Glucose Control, Waist Reduction and Tolerability Additional Cohorts Planned to Determine Maximum Tolerated Dose of DA- 1726 Successfully Completed a Private Placement Resulting in $10 Million in Gross Proceeds $11.2 Million in Cash at End of First Quarter, With the Ad ...